Skip to main content

Abraham Verghese's "Cutting For Stone" paperback on The New York Times best seller list. 2009




Abraham Verghese's "Cutting For Stone"



The New York Times Sunday Book Review

Doctors and Sons

By ERICA WAGNER February 

“I will not cut for stone,” runs the text of the Hippocratic oath, “even for patients in whom the disease is manifest; I will leave this operation to be performed by practitioners, specialists in this art.”

Those words provide an epigraph partway through Abraham Verghese’s first novel, “Cutting for Stone,” and also explain the surname of its narrator, Marion Stone, along with his twin brother, Shiva, and their father, the almost entirely absent surgeon Thomas Stone. Absent in body only: in spirit, Thomas’s disappearance after their birth haunts and drives this book.

Click here to Continue Reading the Review

Abraham Verghese Biography




Abraham Verghese, MD, MACP, is Professor and Linda R. Meier and Joan F. Lane Provostial Professor, and Vice Chair for the Theory and Practice of Medicine at the School of Medicine at Stanford University. He is also a critically acclaimed, best-selling author and a physician with an international reputation for his focus on healing in an era where technology often overwhelms the human side of medicine.

In February 2014, he received a Heinz Award from Teresa Heinz and the Heinz Family Foundation. The awards given annually in the areas of Arts and Humanities; Environment; Human Condition; Public Policy; and Technology, the Economy and Employment, celebrate the enduring spirit of hope and the power of innovation.

For more go to Abraham Verghese Biography






Comments

Post a Comment

Popular posts from this blog

Satish Mehta CEO of Emcure Pharmaceuticals and a Drug Price-Fixing Scandal

The Billionaire And The Drug Price-Fixing Scandal. Forbes article Satish Mehta founded Emcure Pharmaceuticals in 1981. In 2011 Emcure bought U.S. based Heritage Pharmaceuticals founded by Jeffrey Glazer. In 2016 Heritage had U.S. sales of $265 million, 40% of Emcure's total sales. An article in Forbes , by Nathan Vardi and Nazneen Karmali April 25, 2017, says that, " In September 2015, Satish Mehta, the billionaire chief executive of the Indian drug company Emcure Pharmaceuticals, wrote an effusive email congratulating Jeffrey Glazer, the CEO of his U.S. crown jewel, Heritage Pharmaceuticals, on a job well done. "In a short span of 4.5 years, you have taken Heritage to another level," Mehta wrote, adding that he considered Glazer to be "an integral part of our family." In January this year, the article continues, "Glazer pleaded guilty to violating U.S. antitrust law by conspiring with manufacturers to fix the prices of generic drugs. Glazer is
Read more

Why Second Generation Indians in U.S. will not be as Successful:

Image
The Bamboo Ceiling for Asians at U.S. Colleges Extract from "Six Degrees of Education: From Teaching in Mumbai to Investment Research in New York" by Ignatius Chithelen  Published by India Today Online August 3, 2016  Why Second Generation Indians in the U.S. will not be as Successful S ince the 1980s, several million Indians have studied at U.S. colleges. Over a million have stayed on in the U.S. through employment visas and many of them have become successful as professionals and some as entrepreneurs. They include chief executives of major U.S. companies such as Sundar Pichai at Google, Satya Nadella at Microsoft, Shantanu Narayen at software vendor Adobe, Indra Nooyi at Pepsico and Rakesh Sachdev of chemicals and bio-chemicals supplier Sigma-Aldrich. Businesses founded or co-founded by Indians in the U.S. include Cascade Communications, Daisy Systems, Epitome, Hotmail, Junglee, Morphotek, Solar Junction and TIBCO Software.  Some Indian en
Read more